AUB ScholarWorks

Creatinine metabolite, HMH (5-hydroxy-1-methylhydantoin; NZ-419), modulates bradykinin-induced changes in vascular smooth muscle cells

Show simple item record

dc.contributor.author Ienaga K.
dc.contributor.author Sohn M.
dc.contributor.author Naiki M.
dc.contributor.author Jaffa A.A.
dc.contributor.editor
dc.date 2014
dc.date.accessioned 2017-10-05T15:30:58Z
dc.date.available 2017-10-05T15:30:58Z
dc.date.issued 2014
dc.identifier 10.3109/10799893.2013.876039
dc.identifier.isbn
dc.identifier.issn 10799893
dc.identifier.uri http://hdl.handle.net/10938/15309
dc.description.abstract A creatinine metabolite, 5-hydroxy-1-methylhydantoin (HMH: NZ-419), a hydroxyl radical scavenger, has previously been shown to confer renoprotection by inhibiting the progression of chronic kidney disease in rats. In the current study, we demonstrate that HMH modulates the effects of glucose and bradykinin (BK) in vascular smooth muscle cell (VSMC). HMH a novel anti-oxidant drug completely suppressed the expression of B2-kinin receptors (B2KR) in response to high glucose (25 mM) stimulation in VSMC and was also shown to attenuate the effects of BK on VSMC remodeling. HMH inhibited the BK-induced increase in MAPK phosphorylation and attenuated the increase in connective tissue growth factor (CTGF) protein levels in VSMC. These findings suggest that HMH may confer vascular protection against high glucose concentrations and BK-stimulation to ameliorate vascular injury and remodeling through its anti-oxidant properties. © 2014 Informa Healthcare USA, Inc.
dc.format.extent
dc.format.extent Pages: (195-200)
dc.language English
dc.publisher Informa Healthcare; LONDON
dc.relation.ispartof Publication Name: Journal of Receptors and Signal Transduction; Publication Year: 2014; Volume: 34; no. 3; Pages: (195-200);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Creatinine metabolite, HMH (5-hydroxy-1-methylhydantoin; NZ-419), modulates bradykinin-induced changes in vascular smooth muscle cells
dc.type Article
dc.contributor.affiliation Ienaga, K., Nippon-Zoki Pharmaceutical Co., Ltd, l-2 Hiranomachi-nichome, Chuo-ku Osaka 541-0046, Japan
dc.contributor.affiliation Sohn, M., Faculty of Medicine, Medical University of South Carolina, Charleston, SC, United States
dc.contributor.affiliation Naiki, M., Institute of Bio-Active Science (IBAS), Nippon Zoki Pharmaceutical Co., Ltd, Hyogo, Japan
dc.contributor.affiliation Jaffa, A.A., Faculty of Medicine, Medical University of South Carolina, Charleston, SC, United States, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.authorAddress Ienaga, K.; Nippon-Zoki Pharmaceutical Co., Ltd, l-2 Hiranomachi-nichome, Chuo-ku Osaka 541-0046, Japan; email: k-ienaga@nippon-zoki.co.jp
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Biochemistry and Molecular Genetics;
dc.contributor.authorDepartment Biochemistry and Molecular Genetics
dc.contributor.authorDivision
dc.contributor.authorEmail k-ienaga@nippon-zoki.co.jp
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Ienaga, K
dc.contributor.authorInitials Sohn, M
dc.contributor.authorInitials Naiki, M
dc.contributor.authorInitials Jaffa, AA
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Ienaga, K (reprint author), Nippon Zoki Pharmaceut Co Ltd, Chuo Ku, 1-2 Hiranomachi Nichome, Osaka 5410046, Japan.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Aoyagi K, 1997, NEPHROLOGY, V1, P387; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016-S0945-053X(02)00055-0; BRINER VA, 1993, AM J PHYSIOL, V264, pF322; Chintala H, 2012, J BIOL CHEM, V287, P40570, DOI 10.1074-jbc.M112.386565; Christopher J, 2001, AM J PHYSIOL-HEART C, V280, pH1537; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038-265625a0; CLOWES AW, 1983, LAB INVEST, V49, P327; Daniels A, 2009, ACTA PHYSIOL, V195, P321, DOI 10.1111-j.1748-1716.2008.01936.x; Douillet CD, 2000, AM J PHYSIOL-HEART C, V279, pH2829; Endou H, 1996, Eliminating agent for activated oxygen and free radicals, Patent No. [US 6,197,806 B1, 6197806]; Grag UC, 1989, J CLIN INVEST, V83, P1774; Greene EL, 2000, HYPERTENSION, V35, P942; Guha M, 2007, FASEB J, V21, P3355, DOI 10.1096-fj.06-6713com; Hasegawa G, 2011, CLIN NEPHROL, V76, P284, DOI 10.5414-CN107025; Ienaga K, 2011, Drug Discov Ther, V5, P162; Ienaga K, 1989, J CHEM SOC PERK T, V1, P1153; Ienaga K, 2013, EXP TOXICOL PATHOL, V65, P559, DOI 10.1016-j.etp.2012.05.001; Ienaga K, 2007, RENAL FAILURE, V29, P279, DOI 10.1080-08860220701219863; Ienaga K, 2010, BIOL PHARM BULL, V33, P809; IENAGA K, 1994, KIDNEY INT, pS22; Ienaga K, 2009, BIOL PHARM BULL, V32, P1204; IENAGA K, 1991, J CHEM SOC CHEM COMM, P509, DOI 10.1039-c39910000509; JACKSON CL, 1992, HYPERTENSION, V20, P713; Jaffa AA, 2008, J CLIN ENDOCR METAB, V93, P1893, DOI 10.1210-jc.2007-2544; Kamanna VS, 2002, HISTOL HISTOPATHOL, V17, P497; Kichuk MR, 1996, CIRCULATION, V94, P44; Koitabashi N, 2008, EUR J HEART FAIL, V10, P373, DOI 10.1016-j.ejheart.2008.02.011; Kulper EJ, 2008, J HISTOCHEM CYTOCHEM, V56, P785; Kyriakis JM, 2001, PHYSIOL REV, V81, P807; Lai KH, 1996, J CLIN INVEST, V98, P1560, DOI 10.1172-JCI118949; Lee HS, 1999, AM J PHYSIOL-RENAL, V277, pF369; Lille S, 1997, J SURG RES, V70, P178, DOI 10.1006-jsre.1997.5114; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Majack MA, 1985, J CELL BIOL, V101, P1059; MARGOLIUS HS, 1995, HYPERTENSION, V26, P221; Metzler B, 2000, AM J PATHOL, V156, P1875, DOI 10.1016-S0002-9440(10)65061-4; MOMBOULI JV, 1995, ANNU REV PHARMACOL, V35, P679, DOI 10.1146-annurev.pa.35.040195.003335; National Kidney F, 2002, AM J KIDNEY DIS S, V39, pS1; Nguyen TQ, 2008, DIABETES CARE, V31, P1177, DOI 10.2337-dc07-2469; Nolly H, 1990, AM J PHYSIOL, V265, pH1206; Ohnishi H, 1998, J MOL CELL CARDIOL, V30, P2411, DOI 10.1006-jmcc.1998.0799; Panek AN, 2009, PLOS ONE, V25, pe6743; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038-362801a0; SAED GM, 1990, CIRC RES, V67, P510; Sakakibara T, 1998, AM J PHYSIOL-REG I, V274, pR120; San Martin A, 2007, AJP HEART, V42, P1697; Sanchez-Lopez E, 2008, AM J PHYSIOL-RENAL, V294, pF149, DOI 10.1152-ajprenal.00129.2007; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Siragy HM, 1997, HYPERTENSION, V29, P757; Tan Y, 2005, AM J PHYSIOL-RENAL, V288, pF483, DOI 10.1152-ajprenal.00165.2004; Touyz RM, 2003, CAN J PHYSIOL PHARM, V81, P159, DOI 10.1139-Y02-164; Ullian ME, 2005, J AM SOC NEPHROL, V16, P2346, DOI 10.1681-ASN.2004060458; US National Institutes of Health, 1996, NIH PUBLICATION, V85-23; Velarde V, 2004, BIOL RES, V37, P419, DOI 10.4067-S0716-97602004000300007; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038-nrm1173; Winkler JL, 2012, MOL VIS, V18, P874; Yang CM, 2003, J BIOMED SCI, V10, P208, DOI 10.1159-000068713; Yokoi H, 2008, KIDNEY INT, V73, P446, DOI 10.1038-sj.ki.5002722; Zhao M, 2002, APMIS, V110, P458, DOI 10.1034-j.1600-0463.2002.100604.x; Zhu Y, 2001, ARTERIOSCL THROM VAS, V21, P1159, DOI 10.1161-hq0701.092473
dc.description.citedCount
dc.description.citedTotWOSCount 0
dc.description.citedWOSCount 0
dc.format.extentCount 6
dc.identifier.articleNo
dc.identifier.coden JRSTC
dc.identifier.pubmedID
dc.identifier.scopusID 84901258790
dc.identifier.url
dc.publisher.address TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr J. Recept. Signal Transduct.
dc.relation.ispartOfIssue 3
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Journal of Receptors and Signal Transduction
dc.relation.ispartofPubTitleAbbr J. Recept. Signal Transduction
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 34
dc.source.ID WOS:000336792700008
dc.type.publication Journal
dc.subject.otherAuthKeyword BK-B2 receptor
dc.subject.otherAuthKeyword CTGF
dc.subject.otherAuthKeyword HMH (NZ-419)
dc.subject.otherAuthKeyword Intrinsic anti-oxidant
dc.subject.otherAuthKeyword MAPK
dc.subject.otherChemCAS bradykinin, 58-82-2, 5979-11-3
dc.subject.otherChemCAS glucose, 50-99-7, 84778-64-3
dc.subject.otherIndex 5 hydroxy 1 methylhydantoin
dc.subject.otherIndex antioxidant
dc.subject.otherIndex bradykinin
dc.subject.otherIndex bradykinin B2 receptor
dc.subject.otherIndex connective tissue growth factor
dc.subject.otherIndex drug metabolite
dc.subject.otherIndex glucose
dc.subject.otherIndex nz 419
dc.subject.otherIndex unclassified drug
dc.subject.otherIndex animal cell
dc.subject.otherIndex animal experiment
dc.subject.otherIndex animal model
dc.subject.otherIndex antioxidant activity
dc.subject.otherIndex article
dc.subject.otherIndex cell stimulation
dc.subject.otherIndex controlled study
dc.subject.otherIndex enzyme phosphorylation
dc.subject.otherIndex male
dc.subject.otherIndex nonhuman
dc.subject.otherIndex protein expression
dc.subject.otherIndex rat
dc.subject.otherIndex renal protection
dc.subject.otherIndex smooth muscle fiber
dc.subject.otherIndex vascular smooth muscle
dc.subject.otherIndex Western blotting
dc.subject.otherKeywordPlus TISSUE GROWTH-FACTOR
dc.subject.otherKeywordPlus ACTIVATED PROTEIN-KINASE
dc.subject.otherKeywordPlus CHRONIC-RENAL-FAILURE
dc.subject.otherKeywordPlus CHRONIC KIDNEY-DISEASE
dc.subject.otherKeywordPlus INTRINSIC ANTIOXIDANT
dc.subject.otherKeywordPlus DIABETIC-NEPHROPATHY
dc.subject.otherKeywordPlus INCREASED EXPRESSION
dc.subject.otherKeywordPlus MESANGIAL CELLS
dc.subject.otherKeywordPlus MESSENGER-RNA
dc.subject.otherKeywordPlus NITRIC-OXIDE
dc.subject.otherWOS Biochemistry and Molecular Biology
dc.subject.otherWOS Cell Biology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account